MedTrace Logo

Long-Acting Injectable HIV PrEP PROs

NCT07379658 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 128

Last updated 2026-01-30

No results posted yet for this study

Summary

The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews.

Participants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.

Conditions

  • HIV Pre-exposure Prophylaxis

Interventions

OTHER

Interview and survey to evaluate patient reported outcomes between the two medications.

No intervention, the two cohorts will receive the same surveys and interviews.

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • University of Louisville

    collaborator OTHER

  • Anupama Raghuram MD

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-15
Primary Completion
2028-01-31
Completion
2028-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07379658 on ClinicalTrials.gov